Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

被引：114

作者：

Furst, D. E.

Breedveld, F. C.

Kalden, J. R.

Smolen, J. S.

Burmester, G. R.

Sieper, J.

Emery, P.

Keystone, E. C.

Schiff, M. H.

Mease, P.

van Riel, P. L. C. M.

Fleischmann, R.

Weisman, M. H.

Weinblatt, M. E.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90025 USA

[2] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands

[3] Univ Erlangen Nurnberg, Dept Internal Med 3, Inst Clin Immunol, Erlangen, Germany

[4] Vienna Gen Hosp, Inst Rheumatol, Clin Internal Med 3, Vienna, Austria

[5] Charite Hosp, Dept Rheumatol & Clin Immunol, Berlin, Germany

[6] Univ Leeds, Gen Infirm, Dept Rheumatol, Leeds LS1 3EX, W Yorkshire, England

[7] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada

[8] Denver Arthritis Clin, Denver, CO USA

[9] Seattle Rhumatol Assoc, Seattle, WA 98104 USA

[10] Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[11] Univ Texas, SW Med Ctr, Dallas, TX USA

[12] Cedar Sinai Hosp, Los Angeles, CA USA

[13] Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷

关键词：

D O I：

10.1136/ard.2007.081430

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2 / 22

页数：21

共 521 条

[61] International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [J].

Braun, J ;

Pham, T ;

Sieper, J ;

Davis, J ;

van der Linden, S ;

Dougados, M ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :817-824

[62] Infliximab in active early rheumatoid arthritis [J].

Breedveld, FC ;

Emery, P ;

Keystone, E ;

Patel, K ;

Furst, DE ;

Kalden, JR ;

St Clair, EW ;

Weisman, M ;

Smolen, J ;

Lipsky, PE ;

Maini, RN .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (02) :149-155

[63] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[64]

BREEDVELD FC, 2006, EULAR

[65]

Bresnihan B, 2004, J RHEUMATOL, V31, P1103

[66] The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis [J].

Bresnihan, B .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 30 (05) :17-20

[67] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial [J].

Brooklyn, TN ;

Dunnill, MGS ;

Shetty, A ;

Bowden, JJ ;

Williams, JDL ;

Griffiths, CEM ;

Forbes, A ;

Greenwood, R ;

Probert, CS .

GUT, 2006, 55 (04) :505-509

[68] Rituximab in the treatment of antisynthetase syndrome [J].

Brulhart, L. ;

Waldburger, J-M ;

Gabay, C. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :974-975

[69] Response to rituximab in patients with type II cryoglobulinemia [J].

Bryce, Alan H. ;

Dispenzieri, Angela ;

Kyle, Robert A. ;

Lacy, Martha Q. ;

Rajkumar, S. Vincent ;

Inwards, David J. ;

Yasenchak, Christopher A. ;

Kumar, Shaji K. ;

Gertz, Morie A. .

CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02) :140-144

[70] Natural history and therapy of 66 patients with mixed cryoglobulinemia [J].

Bryce, Alan H. ;

Kyle, Robert A. ;

Dispenzieri, Angela ;

Gertz, Morie A. .

AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (07) :511-518

← 2 3 4 5 6 7 8 9 10 11 →